Thrombolytic therapy with use of alteplase (rt-PA) in peripheral arterial occlusive disease: Review of the clinical literature

Journal of Vascular and Interventional Radiology

Volumn 11, Issue 2 I, 2000, Pages 149-161

  Semba, Charles P ^a,b   Murphy, Timothy P ^b   Bakal, Curtis W ^b   Calis, Karim A ^b   Matalon, Terence A S ^b   Chopra, Paramjit ^b   Cole, Patricia E ^b   Comerota, Anthony J ^b   Connors, Buddy ^b   Cynamon, Jacob ^b   Grubbs, Gerald E ^b   Haskal, Ziv ^b   Herbst, Suzanne La Vere ^b   Hunter, David W ^b   Phelps, Kathy ^b   Stump, David ^b   Thomas, Steven ^b   Warner, David L ^b   Zemel, Gerald ^b  

^a STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^b NONE

Author keywords

Alteplase; Arteries, peripheral; Arteries, stenosis or obstruction; Thrombolysis; Tissue plasminogen activator

Indexed keywords

ALTEPLASE; ANISTREPLASE; HEPARIN; PLASMINOGEN ACTIVATOR; RETEPLASE; STREPTOKINASE; UROKINASE;

ANTICOAGULATION; ARTICLE; BLEEDING; CLINICAL TRIAL; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG SAFETY; FIBRINOLYTIC THERAPY; HEPARINIZATION; HUMAN; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; RISK ASSESSMENT;

EID: 0034001707     PISSN: 10510443     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1051-0443(07)61459-6     Document Type: Article

References (80)

1. Mills JL, Porter JM. Basic data related to clinical decision making in acute limb ischaemia. Ann Vasc Surg 1991; 5:96-98.
2. Moran KT, Jewell ER, Persson AV. The role of thrombolytic therapy in surgical practice. Br J Surg 1989; 76:298-304.
3. Miller BV, Sharp WJ, Hoballah JJ, et al. Management of infrainguinal occluded vein bypasses with a combined approach of thrombolysis and surveillance. Arch Surg 1992; 127: 986-989.
4. Ouriel K. Surgery versus thrombolytic therapy in the management of peripheral arterial occlusions. JVIR 1995;6:48S-54S.
5. Difficulties in obtaining sufficient amounts of urokinase (letter). Rockville: Center for Biologics Evaluation and Research, Public Health Service, Food and Drug Administration; December 11, 1998.
6. Important drug warning: dear healthcare provider (letter). Rockville: Center for Biologics Evaluation and Research, Public Health Service, Food and Drug Administration; January 25, 1999.
7. Wooster MB, Luzier AB. Reteplase: a new thrombolytic for the treatment of acute myocardial infarction. Ann Pharmacother 1999; 33:318-324.
8. Anderson JL, Sorensen SG, Moreno FL, et al. Multicenter patency trial of intravenous anistreplase compared with streptokinase in acute myocardial infarction: the TEAM-2 Study Investigators. Circulation 1991; 83:126-140.
9. Andaz S, Shields DA, Scurr JH, Smith PD. Thrombolysis in acute lower limb ischemia. Eur J Vasc Surg 1993; 7:595-603.
10. Working Party on Thrombolysis in the Management of Limb Ischemia. Thrombolysis in the management of lower limb peripheral arterial occlusion: a consensus document. Am J Cardiol 1998; 81:207-218.
11. Braithwaite BD, Buckenham TM, Galland RB, et al on Behalf of the Thrombolysis Study Group. Prospective randomized trial of high-dose versus low-dose tissue plasminogen activator infusion in the management of acute limb ischaemia. Br J Surg 1997; 84:646-650.
12. Bero CJ, Cardella JF, Reddy K, et al. Recombinant tissue plasminogen activator for the treatment of lower extremity peripheral vascular occlusive disease. JVIR 1995;6:571-577.
13. Hess H, Mietaschk A, von Bilderling P, Neller P. Peripheral arterial occlusions: local low-dose thrombolytic therapy with recombinant tissue-type plasminogen activator (rt-PA). Eur J Endovasc Surg 1996; 12:97-104.
14. Koppensteiner R, Minar E, Ahmadi R, Jung M, Ehringer H. Low-doses of recombinant human tissue-type plasminogen activator for local thrombolysis in peripheral arteries. Radiology 1988; 168:877-878.
15. Dawson KJ, Reddy K, Platts AD, Hamilton G. Results of a recently instituted programme of thrombolytic therapy in acute lower limb ischaemia. Br J Surg 1991; 78:409-411.
16. Krause FJ, Endsin O. Lokale katheterlyse der femoralarterie: rt-PA versus urokinase. Fortscjr Röntgenstr 1993; 158:46-48.
17. Verstraete M, Hess H, Mahler F, et al. Femoro-popliteal artery thrombolysis with intra-arterial infusion of recombinant tissue-type activator: report of a pilot trial. Eur J Vasc Surg 1988; 2:155-159.
18. Graor RA, Olin JW, Bacharach M. Comparison of t-PA and urokinase for peripheral arterial thrombolysis. J Vasc Med Biol 1993; 4:311-314.
19. Earnshaw JJ, Westby JC, Gregson RHS, et al. Local thrombolytic therapy of acute peripheral arterial ischaemia with tissue plasminogen activator: a dose-ranging study. Br J Surg 1988; 75:1196-1200.
20. Graor RA, Risius B, Young JR, et al. Peripheral artery and bypass graft thrombolysis with recombinant human tissue-type plasminogen activator. J Vasc Surg 1986; 3:115-124.
21. Berridge DC, Gregson RHS, Hopkinson BR, Makin GS. Intra-arterial thrombolysis using recombinant tissue plasminogen activator (r-TPA): the optimal agent, at the optimal dose? Eur J Vasc Surg 1989; 3:327-332.
22. Risius B, Graor RA, Geisinger MA, et al. Recombinant human tissue-type plasminogen activator for thrombolysis in peripheral arteries and bypass grafts. Radiology 1986; 160:183-188.
23. Lonsdale RJ, Berridge DC, Earnshaw JJ, et al. Recombinant tissue-type plasminogen activator is superior to streptokinase for local intra-arterial thrombolysis. Br J Surg 1992; 79:272-275.
24. Levine EG, Loskutoff DJ. Cultured bovine endothelial cells produce both urokinase and tissue-type plasminogen activators. J Cell Biol 1982; 94:631-636.
25. Wallen P, Pohl G, Bergsdorf N, et al. Purification and characterization of a melanoma cell plasminogen activator. Eur J Biochem 1983; 132: 681-686.
26. Vehar GA, Spellman MW, Keyt BA, et al. Characterization studies of human tissue-type plasminogen activator produced by recombinant DNA technology. Cold Spring Harbor Symp Quant Biol 1986; 51:551-562.
27. Tate KM, Higgins DL, Holmes WE, et al. Functional role of proteolytic cleavage at arginine-275 of human tissue plasminogen activator as assessed by site-directed mutagenesis. Biochemistry 1987; 26:338-343.
28. Lijnen HR, Van Hoef B, De Cock F, Collen D. Effect of fibrin-like stimulators on the activation of plasminogen by tissue-type plasminogen activator (t-PA): studies with active site mutagenized plasminogen and plasmin resistant t-PA. Thromb Haemost 1990; 64:61-68.
29. Activase (Alteplase recombinant) package insert. Genentech, Inc, South San Francisco, CA, 1999.
30. Dotter CT, Rosch J, Seaman AJ. Selective clot-lysis using streptokinase. Radiology 1974; 111:31-37.
31. Riggs P, Ouriel K. Thrombolysis in the treatment of lower extremity occlusive disease. Surg Clin North Am 1995; 75:633-645.
32. Graor RA, Olin J, Bartholomew JR, et al. Efficacy and safety of intra-arterial local infusion of streptokinase, urokinase, or tissue plasminogen activator for peripheral arterial occlusion: a retrospective review. J Vasc Med Biol 1990; 2:310-315.
33. Van Breda A, Katzen BT, Deutsch AS. Urokinase versus streptokinase in local thrombolysis. Radiology 1987; 165:109-111.
34. Berridge DC, Gregson RHS, Makin GS, Hopkinson BR, Makin GS. Randomized trial of intra-arterial recombinant tissue plasminogen activator, intravenous recombinant tissue plasminogen activator and intra-arterial streptokinase in peripheral arterial thrombolysis. Br J Surg 1991; 78:978-995.
35. Yusuf SW, Whitaker SC, Gregson RHS, et al. Prospective randomized comparative study of pulse spray and conventional local thrombolysis. Eur J Endovasc Surg 1995; 10:136-141.
36. NIH Consensus Development Conference. Thrombolytic therapy in thrombosis. Br Med J 1980; 280: 1585-1587.
37. Graor RA, Risius B, Young JR, et al. Thrombolysis of peripheral arterial bypass grafts: surgical thrombectomy compared with thrombolysis. J Vasc Surg 1988; 7:347-355.
38. Krupski WC, Feldman RK, Rapp JH. Recombinant human tissue-type plasminogen activator is an effective agent for thrombolysis of peripheral arteries and bypass grafts: preliminary report. J Vasc Surg 1989; 10:491-500.
39. Holvaert P, Cleemput H, Collen D. Assay of human tissue-type plasminogen activator with an enzyme-linked immunosorbent assay (ELISA) based on three murine monoclonal antibodies to t-PA. Thromb Haemost 1985; 54:684-687.
40. Ouriel K, Shortell CK, Azodo MW, Guitterrez OH, Marder VJ. Acute peripheral arterial occlusion: predictors of success in catheter-directed thrombolytic therapy. Radiology 1994; 93:561-566.
41. Berridge DC, Gregson RHS, Makin GS, Hopkinson BR. Tissue plasminogen activator in peripheral arterial thrombolysis. Br J Surg 1990; 77:179-182.
42. Decrinis M, Pilger E, Stark G, Lafer M, Obernosterer A, Lammer J. A simplified procedure for intra-arterial thrombolysis with tissue-type plasminogen activator in peripheral arterial occlusive disease: primary and long-term results. Eur Heart J 1993; 14:297-305.
43. Spengel FA, Kuffer G, Stiegler H. Efficacy and tolerance of recombinant tissue-type plasminogen activator in patients with thrombotic or embolic occlusions of leg arteries. Clin Invest 1993; 71:323-326.
44. Weidauer TH, Timmermann J. Local intra-arterial thrombolysis with low-dose rt-PA. Fortschr Med 1990; 108:700-702.
45. Schweizer J, Altmann E, Stosslein F, Florek HJ, Kaulen R. Comparison of tissue plasminogen activator and urokinase in the local infiltration thrombolysis of peripheral arterial occlusions. Eur J Radiol 1996; 22:129-132.
46. Weaver FA, Comerota AJ, Youngblood M, et al. Surgical revascularization versus thrombolysis for non-embolic lower extremity native artery occlusions: results of a prospective randomized trial. J Vasc Surg 1996; 24:513-523.
47. Rutherford RB, Baker JD, Ernst C, et al. Recommended standards for reports dealing with lower extremity ischemia: revised version. J Vasc Surg 1997; 26:517-538.
48. Agnelli G. Rationale for bolus t-PA therapy to improve efficacy and safety. Chest 1990; 97:161S-167S.
49. Braithwaite BD, Birch PA, Poskitt KR, Heather BP, Earnshaw JJ. Accelerated thrombolysis with high dose bolus t-PA extends the role of peripheral thrombolysis but may increase the risks. Clin Radiol 1995; 50:747-750.
50. Ward AS, Andaz SK, Bygrave S. Peripheral thrombolysis with tissue plasminogen activator: results of two treatment regimens. Arch Surg 1994; 129:861-865.
51. Ward AS, Andaz SK, Bygrave S. Thromoblysis with tissue-plasminogen activator: results with a high-dose transthrombus technique. J Vasc Surg 1994; 19:503-508.
52. Braithwaite BD. Thrombolysis with tissue-plasminogen activator: results with a high-dose transthrombus technique (letter). J Vasc Surg 1995; 21:540.
53. Yusuf SW, Whitaker SC, Gregson RHS, et al. Immediate and early follow-up results of pulse spray thrombolysis in patients with peripheral ischaemia. Br J Surg 1995; 82:338-340.
54. Armon MP, Yusuf SW, Whitaker SC, Gregson RH, Wenham PW, Hopkinson BR. Results of 100 cases of pulse-spray thrombolysis for acute and subacute leg ischemia. Br J Surg 1997; 84:47-50.
55. Bookstein JJ, Fellmeth B, Roberts A, Valji K, Davis G, Machado T. Pulse-spray pharmacomechanical thrombolysis: preliminary clinical results. Am J Radiol 1989; 152:1097-1100.
56. :56. Yusuf SW, Westby J, Wenham PW, et al. Systemic fibrinolytic effect of pulse-spray thrombolysis with tissue-type plasminogen activator (rt-PA). Fibrinolysis 1994; 8:108-110.
57. Roeren T, Lachenicht B, Dux M, et al. Therapeutic efficacy of pulsed spray lysis in peripheral arterial occlusions. Fortschr Rontgenstrasse 1996; 164:489-495.
58. Kandarpa K, Goldhaber SZ, Meyerovitz MF. Pulse-spray thrombolysis: the "careful analysis." Radiology 1994; 193:320-324.
59. Jørgensen B, Tonnesen KH, Bulow J, et al. Femoral artery recanalization with percutaneous angioplasty and segmentally enclosed plasminogen activator. Lancet 1989; 1:1106-1108.
60. Jørgenson B, Tonnenson KH, Nielsen JD, et al. Segmentally enclosed thrombolysis in percutaneous transluminal angioplasty for femoropopliteal occlusions: a report from a pilot study. Cardiovasc Intervent Radiol 1991; 14:293-298.
61. Tonnesen KH, Holstein P, Andersen E. Femoro-popliteal artery occlusions treated by percutaneous transluminal angioplasty and enclosed thrombolysis: results in 53 patients. Eur J Vasc Surg 1991; 5:429-434.
62. 1. VASA 1998; 27:20-23.
63. Antman EM, Giugliano RP, Gibson CM, et al. Abciximab facilitates the rate and extent of thrombolysis: results of the Thrombolysis in Myocardial Infarction (TIMI) 14 trial. The TIMI 14 investigators. Circulation 1999; 99:2720-2732.
64. Buckenham TM, George CD, Chester JF, et al. Accelerated thrombolysis using pulsed intra-thrombus recombinant human tissue plasminogen activator (rt-PA). Eur J Vasc Surg 1992; 6:237-240.
65. STILE Investigators. Results of a prospective randomized trial evaluating surgery versus thrombolysis for ischemia of the lower extremity: STILE trial. Ann Surg 1994; 220: 251-268.
66. Ouriel K, Shortell CK, deWeese JA, et al. A comparison of thrombolytic therapy with operative revascularization in the initial treatment of acute peripheral arterial ischemia. J Vasc Surg 1994; 19:1021-1030.
67. Ouriel K, Veith FJ, Sasahara AA. Thrombolysis or peripheral arterial surgery (TOPAS): Phase I results. J Vasc Surg 1996; 23:64-73.
68. Ouriel K, Veith FJ, Sasahara AA. A comparison of recombinant urokinase with vascular surgery as initial treatment for acute arterial occlusion of the legs. N Engl J Med 1998; 338:1105-1111.
69. Nilsson L, Albrechtsson U, Jonung T, et al. Surgical treatment versus thrombolysis in acute arterial occlusion: a randomized controlled study. Eur J Vasc Surg 1992; 6:189-193.
70. Hoch JR, Tullis MJ, Archer CW, et al. Thrombolysis versus surgery as the initial management for native artery occlusion: efficacy, safety, and cost. Surgery 1994; 116:649-657.
71. Palfreyman SJ, Michaels JA. Systematic review of intra-arterial thrombolytic therapy for peripheral vascular occlusions (abstract). Br J Surg 1999; 86:704.
72. Meyerovitz MF, Didier D, Vogel J, Soulier-Parmeggiani L, Bounameaux H. Thrombolytic therapy compared with mechanical recanalization in non-acute peripheral arterial occlusions: a randomized trial. JVIR 1995;6:775-781.
73. Pilger E, Decrinis M, Stark G, et al. Thrombolytic treatment and balloon angioplasty in chronic occlusion of the aortic bifurcation. Ann Intern Med 1994; 120:40-44.
74. Otto W, Rowinski O, Malkowski P, Paczkowski P, Pruszynksi B, Karwowski A. Laser angioplasty and thrombolytic treatment for femoral artery occlusion. Radiol Oncol 1995; 29:185-189.
75. Lammer J. Laser angioplasty of peripheral arteries: an epilogue? Cardiovasc Intervent Radiol 1995; 18:1-8.
76. Rauber K, Heidinger KS, Kemkes-Matthes B. Coagulation alterations due to local fibrinolytic therapy with recombinant tissue-type plasminogen activator (rt-PA) in patients with peripheral arterial occlusive disease. Cardiovasc Intervent Radiol 1997; 20:169-173.
77. Ellis PK, Kelly BE, McIlrath EM. The use of recombinant human tissue type plasminogen activator (rt-PA) in both graft and native arteries in the lower limb: results over a 2-year period. J Intervent Radiol 1996; 11:145-147.
78. Lambert AW, Trkulja D, Fox AD, Budd JS, Chalmers AH, Horrocks M. Age-related outcome for peripheral thrombolysis. Eur J Vasc Endovasc Surg 1999; 17:144-148.
79. Von Knorring S, Perakyla T, Edgren J, et al. Thrombolytic treatment of acute or chronic leg ischemia. Ann Chir Gynaecol 1995; 84:369-371.
80. Stump DC, Mann KG. Mechanisms of thrombus formation and lysis. Ann Emerg Med 1988; 17:1138-1147.